Michael Higgins

Michael Higgins has served as a member of our board of directors since February 2015. He is currently the Chief Executive Officer of Kindex Pharmaceuticals. From 2015 through 2019 he served as an Entrepreneur-in-Residence at Polaris Partners.  Prior to Polaris, Mr. Higgins served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals from 2003 through 2014, playing a key role in Ironwood’s evolution from a privately funded discovery organization through its initial public offering and the launch of its first commercial product. Under his leadership, the company was able to raise more than one billion dollars to help support the development of the business during that period. From 1997 through 2003, Mr. Higgins worked at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. While at Genzyme, he was involved with multiple businesses including the Cell Therapy, Gene Therapy, and Orphan Disease business units. Previously, Mr. Higgins served as Chief Financial Officer of Procept, Inc., from 1992 to 1997, and led the company through its initial public offering. He currently serves as a director of Pulmatrix, Inc. and Is Chairman of the Board at Voyager Therapeutics. Mr. Higgins began his pharmaceutical career as a sales representative for Schering-Plough Corporation. He earned his B.S. from Cornell University and holds an M.B.A. from the Amos Tuck School of Business at Dartmouth College.